STX209 · program
Arbaclofen for Autism spectrum disorder
Indications for STX209: Autism spectrum disorder · Phase 2 Multiple sclerosis · Phase 3 Fragile X syndrome · Phase 3
Arbaclofen, a selective GABA-B receptor agonist, for social function and core symptoms in autistic children and adolescents. The idea is that boosting GABA-B inhibition rebalances cortical excitation and inhibition. Seaside Therapeutics' Phase 2 (209AS208, NCT01288716; 150 participants aged 5-21) missed its primary endpoint (ABC Social Withdrawal/Lethargy) but improved clinician-rated CGI-Severity. Seaside stopped development in 2013, and its open-label extension was terminated.
Development timeline
- UpcomingClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.
- missedAIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).↗
- AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.
- Trial startedAIMS-2-CT2 arbaclofen biomarker study starts in autism
- Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.↗
- missedCanadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.↗
- Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.
- missedSeaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.↗
- Seaside open-label extension 209AS209 (NCT01706523) registered as terminated, with primary completion July 2013. Sponsor development of arbaclofen in autism stopped.
- Trial terminatedSeaside terminates the open-label extension of STX209 in autism
- Seaside starts the randomised, placebo-controlled Phase 2 209AS208 (NCT01288716; 150 participants aged 5-21). Primary endpoint: ABC Social Withdrawal/Lethargy.
- Seaside Therapeutics opens study 22003 (NCT00846547), an open-label, flexible-dose Phase 2 of STX209 in autism spectrum disorder.
Readouts
- December 2026AnticipatedRegistry resultsNCT07655115
ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.
- 2026-01-22ReportedFull resultsmissedNCT03682978
AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%). ↗
- 2023-05-05ReportedTopline datamissedNCT03887676
Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures. ↗
- 2016-10-17ReportedFull resultsmissedNCT01288716
Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity. ↗
Clinical trials in Autism spectrum disorder
NCT07655115AIMS-2-CT2Phase 3Recruitingn=103
A Follow-Up Shiftability Study of Arbaclofen With an Open-Label Extension for the Study of Biomarkers in Children and Adolescents With Autism Spectrum Disorders.
NCT03682978AIMS2-CT-01Phase 2Completedn=124
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
NCT03887676ARB-05-2018Phase 2Completedn=90
A Randomized Placebo-controlled Trial of ARBaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD
NCT01706523209AS209Phase 3Discontinuedn=165
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders
NCT01288716209AS208Phase 2Completedn=150
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
NCT0084654722003Phase 2Completedn=32
An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Arbaclofen oral (orally disintegrating) tablets, 5-20 mg BID-TID AIMS-2-TRIALS-CT1 (NCT03682978): orally disintegrating tablets of 5, 10, 15 and 20 mg, flexibly titrated over 5 weeks and stratified by age. Ages 5-11 went from 5 mg BID up to 15 mg TID; ages 12-17 went from 5 mg QD up to 20 mg TID. Treatment lasted 16 weeks. The Canadian ARBA trial (NCT03887676) used the same orally disintegrating tablet strengths. | Oral | Three times daily | — |
Mechanism of action
Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.
| Target | Action | Affinity |
|---|---|---|
| GABA-B receptorprimaryGABBR1 | Agonist | —ⓘ |
← Full STX209 compound page (identity, identifiers, all indications)
Sources
- Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award (2025-08-21, PR Newswire wire copy) — Allos Pharma Inc. (via The AI Journal)
- Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen (2023-09-18, PR Newswire wire copy) — Allos Pharma Inc. (via BioSpace)
- NCT00846547 (22003) — Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01288716 (209AS208) — Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01706523 (209AS209) — Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03682978 (AIMS2-CT-01) — Arbaclofen in Children and Adolescents With ASD — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03887676 (ARB-05-2018) — Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT07655115 (AIMS-2-CT2) — Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th — ClinicalTrials.gov (U.S. National Library of Medicine)
- Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
- Parellada M, et al. Efficacy, safety, and tolerability of arbaclofen in autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial. EClinicalMedicine 2026;92:103760 — EClinicalMedicine (Elsevier) / PubMed
- Trials of arbaclofen for autism yield mixed results (2023-05-05) — The Transmitter (Simons Foundation)
- Veenstra-VanderWeele J, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 2017;42(7):1390-1398 — Neuropsychopharmacology / PubMed